Skip to Content

'
Elizabeth A. Grimm, Ph.D.

Present Title & Affiliation

Primary Appointment

Deputy Division Head for Research Affairs, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Departments of Experimental Therapeutics and Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX
Professor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1979 UCLA School of Medicine, Los Angeles, CA, PHD, Microbiology and Immunobiology
1971 Randolph-Macon Woman's College, Lynchburg, VA, AB, Chemistry

Experience/Service

Other Appointments/Responsibilities

Co-Director, Steering Committee of the Multidisciplinary Melanoma/Skin Cancer Research Program, MDACC, Houston, TX, 1998-present
Research Director, Melanoma and Skin Cancer Program, MDACC, Houston, TX, 1998-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16(6):1834-44, 3/15/2010. e-Pub 3/9/2010. PMCID: PMC2858983.
2. Greene VR, Johnson MM, Grimm EA, Ellerhorst JA. Frequencies of NRAS and BRAF Mutations Increase from the Radial to the Vertical Growth Phase in Cutaneous Melanoma. J Invest Dermatol 129(6):1483-8, 6/2009. e-Pub 11/2008. PMCID: PMC2741006.
3. Uffort DG, Grimm EA, Ellerhorst JA. NF-kappaB Mediates Mitogen-Activated Protein Kinase Pathway-Dependent iNOS Expression in Human Melanoma. J Invest Dermatol 129(1):148-54, 1/2009. e-Pub 7/2008. PMCID: PMC2758038.
4. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Sampson JH, Priebe W, Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14(18):5759-68, 9/15/2008. PMCID: PMC2583362.
5. Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu S. Constitutive Intracellular Production of iNOS and NO in Human Melanoma; Possible role in Regulation of Growth and Resistance to Apoptosis. Nitric Oxide 19(2):133-7, 9/2008. e-Pub 4/22/2008. PMCID: PMC2577016.
6. Ekmekcioglu S, Mumm JB, Udtha M, Chada S, Grimm EA. Killing of Human Melanoma Cells Induced by Activation of Class I Interferon-Regulated Signaling Pathways via MDA-7/IL-24. Cytokine 18(4):241-5, 7/2008. e-Pub 6/2008. PMCID: PMC2582834.
7. Licato LL, Prieto VG, Grimm EA. A novel preclinical model of human malignant melanoma utilizing bioreactor rotating-wall vessels. In Vitro Cell Dev Biol Anim 37:121-6, 2001. PMID: 11370802.

Book Chapters
1. Ekmekcioglu S, Kurzrock R, Grimm EA. Hematopoietic Growth Factors and Cytokines. In: The Molecular Basis of Cancer, 3rd. Ed(s) J Mendelsohn, PM Howley, MA Israel, JW Gray, CB Thompson. Saunders Elsevier: Philadelphia, PA, 605-619, 2008. PMID: 978-1-4160-3703-3.
2. Grimm EA, Hoon DS and Duncan LM. Biomarkers for Cutaneous Melanoma. In: Cutaneous Melanoma, 5th. Ed(s) Balch C, Houghton AN, Sober AJ, Soong SJ, Atkins MB and Thompson JF. Quality Medical Publishing, Inc: St. Louis, 883-897, 2009.

Last updated: 11/29/2010